Last Updated January 28, 2024

 January 28, 2024

Curious about BPC-157 + TB-500 nasal spray?

Then this is the right place. See, BPC-157 and TB-500 are two peptides known to accelerate wound healing and injury recovery. But what might happen if the two combined?

Researchers believe that using BPC-157 and TB-500 together can yield synergistic effects to accelerate cell migration to sites of injury, thus speeding up processes of tissue repair.

While researchers usually administer BPC-157 and TB-500 via injections, there are now nasal spray blends on the market. Using a nasal spray format could have certain advantages in terms of:

  • Convenience
  • Dosing
  • Administration
  • Quicker delivery to the target site

Due to increased interest in administering BPC-157 and TB-500 together, our research team has created this informative guide to discuss the potential benefits and drawbacks of using this peptide blend as a spray.

Buy BPC-157 + TB-500 Nasal Spray Blend from our top-rated vendor...

Disclaimer: contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic peptide derived from an endogenous protein found in human gastric juice. This protein, Body Protection Compound, is vital for normal gastrointestinal tract functioning, and its primary function is to heal and protect the GI lining.

BPC-157 is a fragment of the whole BPC protein and consists of 15 amino acids [1]. While its exact mechanism of action remains unclear, it is known to promote angiogenesis, thus enhancing oxygenation to tissues and accelerating healing processes.

It is continuously researched for a number of therapeutic applications in relation to its healing potential, which could be used to overcome soft and hard tissue injuries, GI disorders, and inflammatory diseases, just to name a few conditions [2, 3, 4, 5, 6].

There has been limited research examining the efficacy of BPC-157 in humans, and the peptide has yet to receive formal approval for any therapeutic use.

What is TB-500?

TB-500 is a synthetic analog of thymosin beta-4 (TB4), a protein found in most human and animal cells. [7]. TB-500 thus exhibits similar behavior and outcomes to TB4 in clinical studies.

It plays an essential role in regenerating and healing injured tissues by upregulating actin and blocking actin polymerization, while also promoting angiogenesis and cell migration [8, 9, 10, 11].

TB-500 became prominent in the early 2000s in horse racing, with reports stating that it could build muscle, promote recovery, decrease inflammation, increase red blood cell count, and stop bleeding in the animals. Although the regulatory bodies did not confirm these performance-enhancing effects, the use of TB-500 was quickly prohibited in the sport [12, 13].

Like BPC-157, TB-500 has not been approved for human use, but is legal for purchase by qualified researchers for laboratory experimentation.

BPC-157 + TB-500 Nasal Spray

BPC-157 + TB-500 Benefits

Ongoing research indicates that both BPC-157 and TB-500 stimulate repair in a number of tissues. However, little is known about the precise effects of the two peptides when administered concurrently.

Here are some of the most notable findings from studies conducted to date.

Tissue Repair and Injury Healing

While BPC-157 is well-known for its ability to maintain healthy GI lining, the peptide is also known to stimulate healing in other tissues, including tendons, ligaments, muscles, and bones. It achieves these effects by promoting fibroblast proliferation, a process vital for wound healing [2, 3, 6].

TB-500 has also been shown to accelerate tissue repair and wound healing by upregulating actin, while blocking acting polymerization. Concurrent administration of the two peptides is thus believed to have more potent healing effects, with research suggesting a synergistic effect to accelerate the migration of fibroblasts and immune system cells to sites of injury [8, 9, 11].

Angiogenesis and Cardiovascular Health

Current animal studies on BPC-157 benefits show that the peptide promotes angiogenesis by upregulating vascular endothelial growth factor (VEGF). Vascular proliferation is vital to improving circulation, managing blood pressure, assisting injury recovery, and potentially reducing cardiovascular risk.

TB-500 also upregulates the expression of VEGF to induce angiogenesis, having been proposed as a potential treatment of cardiac injury. Together, BPC-157 + TB500 could have a substantial effect on promoting cardiovascular health and supporting recovery [14, 15, 16].

Digestive Health

Thanks to the strong cytoprotective properties of Body Protection Compound, BPC-157 also has the potential to aid the GI tract by stabilizing the mucosa membrane. This could be beneficial in the treatment of inflammatory bowel disease and other GI conditions. In addition, BPC-157 has been revealed in animal studies to strengthen the gut-brain axis by fortifying communication between the central nervous system and the GI tract.

Current research suggests TB-500 could promote epithelial repair and growth, and also aid in the treatment of GI conditions. When used together, BPC-157 and TB-500 could provide valuable digestive health support [4, 5, 17, 18].

Immune System Support and Anti-Inflammatory Response

Animal studies indicate that BPC-157 has potent antioxidative properties, which could reduce the inflammatory response in the brain, liver, lung, and other tissues. TB-500 has shown similar anti-inflammatory abilities in animal models. Both peptides exhibit the potential to modulate an immune response to attenuate certain conditions, as a result of which administering BPC-157 and TB-500 together may provide even stronger effects [10, 19, 20].

While these are some of the most promising BPC-157 and TB-500 benefits, research suggests other potential therapeutic applications. These include neuroprotective benefits, mitigating drug toxicity, anti-aging benefits, analgesic effects, and treatment of metabolic disease [21, 22, 23, 24].

BPC-157 + TB-500 Side Effects

We still lack quality human studies into BPC-157 and TB-500 side effects and safety, especially when administered together. However, the research to date indicates that both peptides have favorable safety profiles.

A preclinical safety evaluation of BPC-157 published in Regulatory Toxicology and Pharmacology found this peptide to have a favorable safety profile. BPC-157 was well-tolerated and exhibited no severe toxic effects in mice, rats, rabbits, and dogs. This preclinical data provides an excellent base for human safety and efficacy trials [25].

A randomized, placebo-controlled, single and multiple dose study published in Annals of the New York Academy of Sciences evaluated the safety of TB4, a molecule that is identical to TB-500 in structure and function. The study authors found that intravenous injection of 42mg to 1260mg of TB4 was safe in healthy adults, with no dose limiting toxicities or serious adverse events reported [26].

Despite these excellent findings, researchers should note the potential for minor and transient side effects generally associated peptide administration:

  • Injection site pain
  • Dizziness
  • Headache
  • Fatigue
  • Nausea

Adverse effects may be more common with the use of low-quality peptides from unverified sources. These may contain harmful contaminants, often due to a lack of proper quality testing.

Researchers should accordingly source their BPC-157 and TB-500 blend from a reputable vendor with transparent sourcing processes, third-party lab testing, and ethical marketing.

Researchers should pay attention to the latest dosing guidelines and handling practices as established by experts. Immediately discontinue peptide administration in the event of a severe adverse reaction in research.

BPC-157 + TB-500 Dosage Guide

Since BPC-157 and TB-500 are not approved for human use, there are no official dosage guidelines for either peptide for any use.

However, based on the research to date, researchers will want to consider the following guidelines when when administering these peptides:

  • Subcutaneous and intramuscular injections are considered more effective due to enhanced bioavailability, but using BPC-157 + TB-500 nasal spray could have certain advantages depending on the therapeutic objective and study design.
  • The optimal dosing schedule will vary depending on the desired therapeutic outcome and size of the subject.
  • Research suggests a TB-500 dose of 2-5mg administered twice weekly for four to eight weeks. In some cases, researchers prefer using a higher initial dose and lower maintenance doses.
  • In joint, tendon, and ligament healing contexts, BPC-157 is typically administered daily at a dose of 250mcg to 500mcg.
  • Most courses of both BPC-157 and TB-500 do not exceed 8 weeks of use.

Sample BPC-157 + TB-500 Nasal Spray Dosing Protocol

For reference, we include a sample dosing protocol for researchers using a nasal spray that contains 10mg of BPC-157 and 50mg of TB-500, such as the BPC-157 + TB-500 nasal spray from Limitless Life  our preferred peptides vendor.

Assuming the blend described above, researchers may administer the nasal spray as follows:

  • BPC-157 + TB-500 Dosage: 500mcg BPC-157 + 2.5mg TB-500 administered daily. Administer at once or at different times via nasal spray, alternating nostrils. For most research protocols, 4-6 sprays per day are needed. On a weekly basis, the research subject is receiving roughly 3.5mg of BPC-157 and 17.5mg of TB-500.
  • Course Duration: 20 days
  • Notes: This protocol requires one BPC-157 + TB-500 nasal spray bottle per subject for the course duration. Researchers can adjust dosing and duration based on the desired therapeutic effects, target area, severity of condition, and other factors.

Knowledge in this area is constantly evolving, so researchers are encouraged to stay abreast of the latest research and developments regarding BPC-157 and TB-500.

BPC-157 + TB-500 Nasal Spray | The A-Z Guide

While BPC-157 and TB-500 are usually administered via injection due to high bioavailability, researchers may prefer using nasal spray for any number of reasons.

Intranasal administration may be an excellent approach for certain therapeutic effects. For example, researchers examining the impact of these two peptides on brain health and cognitive performance may prefer to use nasal spray due to quick absorption and rapid response.

Intranasal administration of peptides has been shown effective due to the following factors [27]:

  • Large surface area
  • Permeable endothelial membrane
  • Elimination of first-pass effect
  • Good circulation

Researchers who wish to administer the BPC-157 and TB-500 blend via a nasal spray are encouraged to take certain precautions to ensure delivery of maximum bioavailability:

  • To optimize absorption: Wait up to one minute between sprays via the same nostril to prevent oversaturating the nasal membrane and thus losing peptide due to swallowing.
  • Head position: Ensure that the subject is in a tilted head position; this prevents loss from the bottom of the nose.
  • Clear any nasal congestion: Before administering the peptide via spray, clear the nasal membrane. This minimizes blockage of the nasal membrane and also optimizes absorption.
  • Take care: Keep the spray pump clean and refrigerated at all times to prevent contamination and peptide degradation.

Apart from understanding the mechanics of peptide nasal absorption and following sound practices for administering peptides, researchers should perform due diligence when selecting an appropriate nasal spray product.

The research chemicals market has become saturated in recent years, with some vendors offering products of questionable quality and effectiveness and reviewers reporting a range of experiences with their peptide nasal spray purchases.

Researchers should consider several factors when buying a BPC-157 + TB-500 nasal spray, including peptide quality, third-party laboratory testing, customer service quality, and satisfaction guarantees.

BPC-157 + TB-500 Nasal Spray

Where to Buy BPC-157 + TB-500 Nasal Spray Online? | 2024 Edition

Researchers searching for BPC-157 + TB-500 nasal spray online have several options.

Yet for the reasons we discussed above, researchers should carefully vet potential vendors for reputation, certifications, and consumer-friendly policies.

In our experience, Limitless Life stands apart from other online vendors for their peptide-based nasal products.

They currently offer an excellent and powerful BPC-157 + TB+500 nasal spray.

Here are some reasons why we endorse Limitless Life:

  • Lab-Tested Peptides: Limitless Life performs rigorous in-house lab testing and additionally collaborates with third-party labs to analyze their products for quality and purity.
  • Potent Products: The vendor offers their spray products with potent formulations that actually work in research settings. While many companies add TB-500 for marketing at doses that do nothing, Limitless Life offers 50mg of TB-500. This formulation is sure to get results for researchers.
  • Reliable Shipping: Limitless Life provides rapid and reasonable shipping options. This includes a FedEx two-day shipping option that is standard, along with some of the best shipping insurance in the industry. They also offer rapid international shipping.
  • Flexible Policies on Returns and Reshipments: Understanding the unique needs of researchers, Limitless Life offers a great return and reship policy. This offers peace of mind for researchers.

Buy BPC-157 + TB-500 Nasal Spray Blend from our top-rated vendor...

BPC-157 + TB-500 Nasal Spray vs. Injectable

Although researchers are increasingly testing peptides in nasal spray format, injection still remains the gold standard form of administering both BPC-157 and TB-500 for a systemic effect.

Animal studies involving parenteral injections of both BPC-157 and TB-500 have reported high bioavailability with this route of administration [4, 5, 11, 15].

A BPC-157 and TB-500 nasal spray product, by contrast, will likely not replicate the same level and consistency of bioavailability compared to subcutaneous injection. In other words, subjects will likely need a higher dose of intranasal spray to achieve comparable results to injections.

Yet a nasal spray product will typically arrive prepared in a metered spray bottle for researchers to use right away. In comparison, researchers who administer peptide injections will receive their peptides in the form of lyophilized powder, which must be reconstituted with a sterile solvent like bacteriostatic water.

Using a nasal spray eliminates the need for reconstitution, and dosing is straightforward with the metered spray format. Each product has a fixed amount of BPC-157 and TB-500, so researchers know the exact amount of each peptide in every spray.

Many BPC-157 + TB-500 nasal sprays are stable at room temperature, which makes storage more convenient. In comparison, most manufacturers recommend storing lyophilized powder at a lower temperature, away from bright light. Accordingly, BPC-157 + TB-500 nasal sprays are easier to transport without the researcher having to worry about peptide degradation.

Additionally, both the BPC-157 and TB-500 peptides are quickly cleared from the nasal cavity after administration, which leads to a quick systemic response. This type of administration does not cause irritation, pain, or tenderness, which are common side effects of injections.

A nasal spray is thus generally easier to administer than an intramuscular or subcutaneous injection. In addition, intranasal administration offers the potential advantages of a more rapid onset of action and avoidance of first-pass metabolism [28].

Whether the research will call for a BPC-157 + TB-500 nasal spray or injections will depend on the nature of trial design.

If there is a risk of poor subject compliance with injections and/or a need for convenient administration, then researchers should certainly consider a BPC-157 + TB-500 nasal spray.

If there is a need for maximum bioavailability, researchers will likely want to procure an injectable peptide blend.

BPC-157 + TB-500 Nasal Spray

BPC-157 + TB-500 Nasal Spray | Verdict

Research suggests that BPC-157 and TB-500 produce synergistic effects to enhance injury recovery and wound healing in test subjects.

Additionally, the peptides may jointly improve other processes like digestive health, immune response, and cardiovascular function.

Despite a potential sacrifice in bioavailability over injections, some researchers may wish to use a BPC-157 + TB-500 nasal spray to study the effects of concurrent administration.

Storing and administering a peptide nasal spray is easy and convenient, and there is ample evidence to support the effectiveness of intranasal administration of peptides.

Based on criteria including lab results, customer service, and shipping speed, we recommend Limitless Life as the best place to source BPC-157 and TB-500 nasal spray online.


  1. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 9941957; [cited 2023 Jan. 31]. Available from:
  2. Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010 Sep;28(9):1155-61. doi: 10.1002/jor.21107. PMID: 20225319.
  3. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019 Aug;377(2):153-159. doi: 10.1007/s00441-019-03016-8. Epub 2019 Mar 27. PMID: 30915550.
  4. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, Zoricic Z, Vrcic H, Sebecic B. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19(1):126-32. doi: 10.2174/092986712803414015. PMID: 22300085.
  5. Vuksic T, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, Cesarec V, Berkopic L, Keller N, Blagaic AB, Kokic N, Jelic I, Geber J, Anic T, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768-77. doi: 10.1007/s00595-006-3498-9. Epub 2007 Aug 27. PMID: 17713731.
  6. Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y, Zhang Y, Zhang W. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015 Apr 30;9:2485-99. doi: 10.2147/DDDT.S82030. PMID: 25995620; PMCID: PMC4425239.
  7. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 16132341, Thymosin beta4; [cited 2023 Jan. 31]. Available from:
  8. Maar K, Hetenyi R, Maar S, Faskerti G, Hanna D, Lippai B, Takatsy A, Bock-Marquette I. Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies. Cells. 2021 May 28;10(6):1343. doi: 10.3390/cells10061343. PMID: 34071596; PMCID: PMC8228050.
  9. Guarnera G, DeRosa A, Camerini R; 8 European sites. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010 Apr;1194:207-12. doi: 10.1111/j.1749-6632.2010.05490.x. PMID: 20536470.
  10. Belsky JB, Rivers EP, Filbin MR, Lee PJ, Morris DC. Thymosin beta 4 regulation of actin in sepsis. Expert Opin Biol Ther. 2018 Jul;18(sup1):193-197. doi: 10.1080/14712598.2018.1448381. Epub 2018 Mar 6. PMID: 29508629; PMCID: PMC6556887.
  11. Li X, Zheng L, Peng F, Qi C, Zhang X, Zhou A, Liu Z, Wu S. Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing. Protein Expr Purif. 2007 Dec;56(2):229-36. doi: 10.1016/j.pep.2007.08.011. Epub 2007 Sep 4. PMID: 17923415.
  12. The Racing Medication and Testing Consortium (RMTC). “Drug Bulletins on Purple Pain and TB-500.” RMTC, 2 July 2013,
  13. The Racing Medication and Testing Consortium (RMTC). Thymosin β Bulletin – RMTC. Nov. 2013,
  14. Knezevic M, Gojkovic S, Krezic I, Zizek H, Malekinusic D, Vrdoljak B, Vranes H, Knezevic T, Barisic I, Horvat Pavlov K, Drmic D, Staroveski M, Djuzel A, Rajkovic Z, Kolak T, Kocman I, Lovric E, Milavic M, Sikiric S, Tvrdeic A, Patrlj L, Strbe S, Kokot A, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P. Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. Biomedicines. 2021 May 26;9(6):609. doi: 10.3390/biomedicines9060609. PMID: 34073625; PMCID: PMC8229949.
  15. Spurney CF, Cha HJ, Sali A, Pandey GS, Pistilli E, Guerron AD, Gordish-Dressman H, Hoffman EP, Nagaraju K. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010 Jan 29;5(1):e8976. doi: 10.1371/journal.pone.0008976. PMID: 20126456; PMCID: PMC2813286.
  16. Xing, Yuan, et al. “Progress on the Function and Application of Thymosin β4.” Frontiers, Frontiers, 26 Nov. 2021, Available from:
  17. Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022 Mar;17(3):482-487. doi: 10.4103/1673-5374.320969. PMID: 34380875; PMCID: PMC8504390.
  18. Cesarec V, Becejac T, Misic M, Djakovic Z, Olujic D, Drmic D, Brcic L, Rokotov DS, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. Eur J Pharmacol. 2013 Feb 15;701(1-3):203-12. doi: 10.1016/j.ejphar.2012.11.055. Epub 2012 Dec 7. PMID: 23220707.
  19. Deek SA. BPC 157 as Potential Treatment for COVID-19. Med Hypotheses. 2021 Nov 9;158:110736. doi: 10.1016/j.mehy.2021.110736. Epub ahead of print. PMID: 34798584; PMCID: PMC8575535.
  20. Park JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020;26(25):2971-2981. doi: 10.2174/1381612826666200523180301. PMID: 32445447.
  21. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Safic H, Suran J, Rak D, Dzidic S, Vrcic H, Sebecic B. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83. doi: 10.2174/13816128130111. PMID: 22950504.
  22. Zhu J, Su LP, Ye L, Lee KO, Ma JH. Thymosin beta 4 ameliorates hyperglycemia and improves insulin resistance of KK Cg-Ay/J mouse. Diabetes Res Clin Pract. 2012 Apr;96(1):53-9. doi: 10.1016/j.diabres.2011.12.009. Epub 2012 Jan 3. PMID: 22217673.
  23. Gjurasin M, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, Kolenc D, Radic B, Seiwerth S, Sikiric P. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010 Feb 25;160(1-3):33-41. doi: 10.1016/j.regpep.2009.11.005. Epub 2009 Nov 10. PMID: 19903499.
  24. SikiriĆ, P., Gyires, K., Seiwerth, S. et al. The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacology 2, 121–127 (1993).
  25. Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, Zhang W, Wang S, Zhang K, He L, Zhang W, Zhang C, Hao Q, Zhang Y, Li M, Li W. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020 Jul;114:104665. doi: 10.1016/j.yrtph.2020.104665. Epub 2020 Apr 22. PMID: 32334036.
  26. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010 Apr;1194:223-9. doi: 10.1111/j.1749-6632.2010.05474.x. PMID: 20536472.
  27. Türker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci. 2004 Jun;26(3):137-42. doi: 10.1023/b:phar.0000026823.82950.ff. PMID: 15230360.
  28. Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012 Jun;134(3):366-79. doi: 10.1016/j.pharmthera.2012.03.003. Epub 2012 Mar 23. PMID: 22465159.

Scientifically Fact Checked by:

David Warmflash, M.D.

Table of Contents
    Add a header to begin generating the table of contents